← Leaderboards
Alan David Levine
Case Western Reserve University
$25,871,674
Attributed
$25,871,674
Total exposure
16
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $5.5M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$42,085,361 · 17
By mechanism
P30$24,472,379 · 6
R01$9,789,051 · 4
DP1$4,088,975 · 1
P01$1,925,171 · 3
T32$919,035 · 1
R21$890,750 · 2
Top collaborators
No co-investigators on record.
Most similar at Case Western Reserve University
Same institution · by research overlap
- Michael Marcel Lederman$51,371,852
- Yiping W Han$10,902,264
- Derek W Abbott$15,447,395
- Eric Pearlman$20,900,586
Others in their field
Top investigators on “Innovation”
- David R. Weir · University Of Michigan At Ann Arbor$382,307,654
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$319,874,172
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$311,654,401
- Richard A Gibbs · Baylor College Of Medicine$300,634,418
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Judith S. Currier · University Of California Los Angeles$271,752,220
Research focus
InnovationResearch PersonnelCommunitiesCellsProgramsClinical ResearchSystems BiologyMolecularFundingExposure ToIntestinal MucosaHomeostasisChronicUnited States National Institutes Of HealthFacultyMentorsResourcesAcquired Immunodeficiency SyndromeServicesMedicineMental HealthAwardNational Institute Of Drug AbuseComorbidity
Grant awards (82)
CWRU Center for Excellence on the Impact of Substance Use on HIV$3,215,234
P30 · FY2025 · DA · contact PI
Administrative Core A$697,409
P30 · FY2025 · DA · contact PI
Core B: Developmental$533,307
P30 · FY2025 · AI · contact PI
Pilot Research Project Core E$320,120
P30 · FY2025 · DA · contact PI
CWRU Center for Excellence on the Impact of Substance Use on HIV$3,215,717
P30 · FY2024 · DA · contact PI
Administrative Core A$697,409
P30 · FY2024 · DA · contact PI
Core B: Developmental$502,998
P30 · FY2024 · AI · contact PI
Core B: Developmental$395,644
P30 · FY2024 · AI · contact PI
Pilot Research Project Core E$320,120
P30 · FY2024 · DA · contact PI
CWRU Center for Excellence on the Impact of Substance Use on HIV$3,215,717
P30 · FY2023 · DA · contact PI
Administrative Core A$697,409
P30 · FY2023 · DA · contact PI
Core B: Developmental$494,827
P30 · FY2023 · AI · contact PI
Pilot Research Project Core E$320,120
P30 · FY2023 · DA · contact PI
Core B: Developmental$241,291
P30 · FY2023 · AI · contact PI
Core B: Developmental$240,018
P30 · FY2023 · AI · contact PI
Core B: Developmental$223,109
P30 · FY2023 · AI · contact PI
CWRU Center for Excellence on the Impact of Substance Use on HIV$79,015
P30 · FY2023 · DA · contact PI
CWRU Center for Excellence on the Impact of Substance Use on HIV$3,213,141
P30 · FY2022 · DA · contact PI
Administrative Core A$697,409
P30 · FY2022 · DA · contact PI
Core B: Developmental$492,528
P30 · FY2022 · AI · contact PI
Pilot Research Project Core E$320,120
P30 · FY2022 · DA · contact PI
CWRU Center for Excellence on the Impact of Substance Use on HIV$79,015
P30 · FY2022 · DA · contact PI
CWRU Center for Excellence on the Impact of Substance Use on HIV$3,195,848
P30 · FY2021 · DA · contact PI
Administrative Core A$697,410
P30 · FY2021 · DA · contact PI
Pilot Research Project Core E$320,120
P30 · FY2021 · DA · contact PI
Identification of immune protective pathways dysregulated by opioid use in HIV infection, using a systems biology-based approach, toward the goal of pharmacological restoration of immune function$14,168
R01 · FY2021 · DA · contact PI
Identification of immune protective pathways dysregulated by opioid use in HIV infection, using a systems biology-based approach, toward the goal of pharmacological restoration of immune function$813,788
R01 · FY2020 · DA · contact PI
Training Program in HIV Cure$204,876
T32 · FY2020 · AI · contact PI
Identification of immune protective pathways dysregulated by opioid use in HIV infection, using a systems biology-based approach, toward the goal of pharmacological restoration of immune function$5,886
R01 · FY2020 · DA · contact PI
Identification of immune protective pathways dysregulated by opioid use in HIV infection, using a systems biology-based approach, toward the goal of pharmacological restoration of immune function$848,658
R01 · FY2019 · DA · contact PI
Repairing the intestinal epithelium from the dual action of HIV and drug use$792,500
DP1 · FY2019 · DA · contact PI
Training Program in HIV Cure$107,886
T32 · FY2019 · AI · contact PI
Identification of immune protective pathways dysregulated by opioid use in HIV infection, using a systems biology-based approach, toward the goal of pharmacological restoration of immune function$70,632
R01 · FY2019 · DA · contact PI
Repairing the intestinal epithelium from the dual action of HIV and drug use$67,200
DP1 · FY2019 · DA · contact PI
Identification of immune protective pathways dysregulated by opioid use in HIV infection, using a systems biology-based approach, toward the goal of pharmacological restoration of immune function$848,658
R01 · FY2018 · DA · contact PI
Repairing the intestinal epithelium from the dual action of HIV and drug use$792,500
DP1 · FY2018 · DA · contact PI
Training Program in HIV Cure$147,682
T32 · FY2018 · AI · contact PI
Repairing the intestinal epithelium from the dual action of HIV and drug use$67,200
DP1 · FY2018 · DA · contact PI
Identification of immune protective pathways dysregulated by opioid use in HIV infection, using a systems biology-based approach, toward the goal of pharmacological restoration of immune function$64,746
R01 · FY2018 · DA · contact PI
Identification of immune protective pathways dysregulated by opioid use in HIV infection, using a systems biology-based approach, toward the goal of pharmacological restoration of immune function$813,788
R01 · FY2017 · DA · contact PI
Repairing the intestinal epithelium from the dual action of HIV and drug use$792,500
DP1 · FY2017 · DA · contact PI
Training Program in HIV Cure$230,942
T32 · FY2017 · AI · contact PI
Identification of immune protective pathways dysregulated by opioid use in HIV infection, using a systems biology-based approach, toward the goal of pharmacological restoration of immune function$813,788
R01 · FY2016 · DA · contact PI
Repairing the intestinal epithelium from the dual action of HIV and drug use$784,575
DP1 · FY2016 · DA · contact PI
Training Program in HIV Cure$227,649
T32 · FY2016 · AI · contact PI
Repairing the intestinal epithelium from the dual action of HIV and drug use$792,500
DP1 · FY2015 · DA · contact PI
Loss of Intestinal Barrier Function in HIV infection$345,081
P01 · FY2010 · AI · contact PI
Extracellular Matrix in Inflammatory Bowel Disease$342,519
R01 · FY2010 · DK · contact PI
Redox regulation of intestinal T cells$235,500
R21 · FY2010 · AI · contact PI
Extracellular Matrix in Inflammatory Bowel Disease$363,232
R01 · FY2009 · DK · contact PI
Loss of Intestinal Barrier Function in HIV infection$338,496
P01 · FY2009 · AI · contact PI
Redox regulation of intestinal T cells$196,250
R21 · FY2009 · AI · contact PI
Loss of Intestinal Barrier Function in HIV infection$358,766
P01 · FY2008 · AI · contact PI
Identification and Regulation of Defensins in Human Mucosal Tissue$47,324
P30 · FY2008 · AR · contact PI
Mucosal T Cells: Is Tolerance Floating on Lipid Rafts$253,876
R01 · FY2007 · AI · contact PI
The Extracellular Matrix Inflammatory Bowel Disease$320,286
R01 · FY2006 · DK · contact PI
Mucosal T Cells: Is Tolerance Floating on Lipid Rafts$261,459
R01 · FY2006 · AI · contact PI
The Extracellular Matrix Inflammatory Bowel Disease$327,994
R01 · FY2005 · DK
Mucosal T Cells: Is Tolerance Floating on Lipid Rafts$267,750
R01 · FY2005 · AI
The Extracellular Matrix Inflammatory Bowel Disease$327,994
R01 · FY2004 · DK
Mucosal T Cells: Is Tolerance Floating on Lipid Rafts$267,750
R01 · FY2004 · AI
The Extracellular Matrix Inflammatory Bowel Disease$327,994
R01 · FY2003 · DK
Mucosal T Cells: Is Tolerance Floating on Lipid Rafts$267,750
R01 · FY2003 · AI
DETACHMENT INDUCED APOPTOSIS IN INTESTINAL EPITHELIUM$252,074
R01 · FY2003 · CA
DETACHMENT INDUCED APOPTOSIS IN INTESTINAL EPITHELIUM$129,768
R01 · FY2003 · CA
The Extracellular Matrix Inflammatory Bowel Disease$371,025
R01 · FY2002 · DK
DETACHMENT INDUCED APOPTOSIS IN INTESTINAL EPITHELIUM$245,358
R01 · FY2002 · CA
Core--Animal facility$147,138
P01 · FY2002 · DK
Transition from early to late colitis--IL 12 regulation$147,138
P01 · FY2002 · DK
DETACHMENT INDUCED APOPTOSIS IN INTESTINAL EPITHELIUM$126,435
R01 · FY2002 · CA
DETACHMENT INDUCED APOPTOSIS IN INTESTINAL EPITHELIUM$238,839
R01 · FY2001 · CA
MUCOSAL T CELLS--IS TOLERANCE FLOATING ON LIPID RAFTS?$229,500
R21 · FY2001 · AI
EXTRACELLULAR MATRIX IN INFLAMMATORY BOWEL DISEASE$216,735
R01 · FY2001 · DK
Core--Animal facility$147,138
P01 · FY2001 · DK
Transition from early to late colitis--IL 12 regulation$147,138
P01 · FY2001 · DK
DETACHMENT INDUCED APOPTOSIS IN INTESTINAL EPITHELIUM$123,197
R01 · FY2001 · CA
DETACHMENT INDUCED APOPTOSIS IN INTESTINAL EPITHELIUM$19,976
R01 · FY2001 · CA
DETACHMENT INDUCED APOPTOSIS IN INTESTINAL EPITHELIUM$232,506
R01 · FY2000 · CA
MUCOSAL T CELLS--IS TOLERANCE FLOATING ON LIPID RAFTS?$229,500
R21 · FY2000 · AI
EXTRACELLULAR MATRIX IN INFLAMMATORY BOWEL DISEASE$210,422
R01 · FY2000 · DK
Core--Animal facility$147,138
P01 · FY2000 · DK
Transition from early to late colitis--IL 12 regulation$147,138
P01 · FY2000 · DK